Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($1.36), $0.54 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.